QTRX

Quanterix Corp

8 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 26

Appointment of a seasoned COO to drive commercial scaling and operational efficiency.

management change

70%

bearishMay 26

Increased executive compensation and equity grants may impact short-term cash burn.

capital raise

30%

bearishMay 6

Net loss of $17.5 million persists despite revenue growth.

earnings miss

60%

bearishMay 6

Gross margin declined from 49% to 43% due to acquisition mix and integration costs.

margin compression

40%

bullishMay 6

Integration of Akoya Biosciences drove a 20% increase in total quarterly revenue.

acquisition

70%

bullishMay 6

Submitted 510(k) premarket notification to the FDA for Alzheimer's blood test.

regulatory action

80%

bearishMay 6

Net loss of $17.5 million persists despite revenue growth.

earnings miss

60%

bearishMay 6

Gross margin declined from 49% to 43% due to acquisition mix and integration costs.

margin compression

40%

bullishMay 6

Integration of Akoya Biosciences drove a 20% increase in total quarterly revenue.

acquisition

70%

bullishMay 6

Submitted 510(k) premarket notification to the FDA for Alzheimer's blood test.

regulatory action

80%

bearishMay 6

Net loss of $17.5 million persists despite revenue growth.

earnings miss

60%

bearishMay 6

Gross margin declined from 49% to 43% due to acquisition mix and integration costs.

margin compression

40%

bullishMay 6

Integration of Akoya Biosciences drove a 20% increase in total quarterly revenue.

acquisition

70%

bullishMay 6

Submitted 510(k) premarket notification to the FDA for Alzheimer's blood test.

regulatory action

80%

bearishMay 6

Net loss of $17.5 million persists despite revenue growth.

earnings miss

60%

bearishMay 6

Gross margin declined from 49% to 43% due to acquisition mix and integration costs.

margin compression

40%

bullishMay 6

Integration of Akoya Biosciences drove a 20% increase in total quarterly revenue.

acquisition

70%

bullishMay 6

Submitted 510(k) premarket notification to the FDA for Alzheimer's blood test.

regulatory action

80%

bearishMay 6

Net loss of $17.5 million persists despite revenue growth.

earnings miss

60%

bearishMay 6

Gross margin declined from 49% to 43% due to acquisition mix and integration costs.

margin compression

40%

bullishMay 6

Integration of Akoya Biosciences drove a 20% increase in total quarterly revenue.

acquisition

70%

bullishMay 6

Submitted 510(k) premarket notification to the FDA for Alzheimer's blood test.

regulatory action

80%

bearishMay 6

Net loss of $17.5 million persists despite revenue growth.

earnings miss

60%

bearishMay 6

Gross margin declined from 49% to 43% due to acquisition mix and integration costs.

margin compression

40%

bullishMay 6

Integration of Akoya Biosciences drove a 20% increase in total quarterly revenue.

acquisition

70%

bullishMay 6

Submitted 510(k) premarket notification to the FDA for Alzheimer's blood test.

regulatory action

80%

bearishMay 6

Net loss of $17.5 million persists despite revenue growth.

earnings miss

60%

bearishMay 6

Gross margin declined from 49% to 43% due to acquisition mix and integration costs.

margin compression

40%

bullishMay 6

Integration of Akoya Biosciences drove a 20% increase in total quarterly revenue.

acquisition

70%

bullishMay 6

Submitted 510(k) premarket notification to the FDA for Alzheimer's blood test.

regulatory action

80%

Filing History

8-KMay 26, 2026

Quanterix's 8-K filing details a significant leadership restructuring aimed at bridging the gap between technical innovation and commercial viability. The appointment of a seasoned operational executive as COO, paired with the movement of the former COO into a product-focused role, indicates a corporate maturity phase where execution is now prioritized over pure R&D. The success of this transition depends on whether Catalano can translate his operational background into tangible margin expansion and revenue acceleration, or if the increased executive spend will simply weigh on the company's bottom line.

10-QMay 6, 2026

The Q1 2026 filing presents a company at a critical crossroads, where the success of a massive corporate integration meets a challenging macroeconomic environment for life sciences research. The acquisition of Akoya has successfully diversified the revenue stream and provided a necessary scale boost, but it has also introduced significant integration overhead and a reliance on non-recurring accounting adjustments to smooth over operating losses. The $19.8 million impairment charge for IPR&D assets highlights the risks inherent in these strategic pivots. Ultimately, the investment thesis now hinges on two primary factors: the execution of the $85 million in annualized cost synergies and the regulatory outcome of the FDA 510(k) submission for Alzheimer's detection. If Quanterix can stabilize its legacy research business while converting its diagnostic pipeline into a reimbursed clinical reality, it may reach its breakeven goal. However, the continued decline in federal funding remains a systemic headwind that could offset these strategic gains.